ArticleInflammopharmacology2025
Adjunctive zinc supplementation with methotrexate improves therapeutic outcomes in an animal model of arthritis.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc is an essential micronutrient necessary for regulating numerous physiological functions and cellular mechanisms, including bone remodelling and immune regulation. Zinc deficiency is associated with rheumatoid arthritis (RA), as loss of zinc homeostasis can impair the activation and maturation of immune cells. An imbalanced immune response is a hallmark of RA. This study aimed to compare the potential of methotrexate (MTX) monotherapy with a combination of MTX and two organic zinc compounds-zinc aspartate and zinc citrate-administered at a therapeutic dose of 50 mg/day, on clinical, biochemical, immunological, and radiological parameters of polyarthritis in a collagen-induced arthritis (CIA) model. Results showed that combination treatments with zinc compounds at this therapeutic level significantly improved oxidative stress markers (GSH, CAT, SOD, NO, MPO, ELA, LPO), serological biomarkers (anti-CCP, CRP), pro-inflammatory mediators (COX-2, NF-κB-p65), pro-inflammatory cytokines (IL-6, IL-1β, TNF-α, IFN-γ), and anti-inflammatory cytokines (IL-10, TGF-β1) compared to the CIA group and MTX monotherapy. Clinical signs, molecular, radiological, and histological analyses of the ankle joints in arthritic rats aligned with these findings. Overall, the results suggest that combining zinc compounds with MTX yields better outcomes in reducing arthritis severity, oxidative stress, and inflammatory markers compared to MTX monotherapy.
Indexed as
Identifiers
41105345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.